James Hamilton

机构：Arrowhead Pharmaceuticals (United States), Madison Group (United States) · ORCID：0000-0002-5494-2744

发表论文 138 篇 · 总被引 3298 次 · h-index 22

代表论文

• Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989 (2024 · Gut · 被引 42)
• Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA) (2024 · Gastroenterology · 被引 29)
• Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial (2025 · The Lancet Diabetes & Endocrinology · 被引 19)
• Abstract 4363704: YOSEMITE Rationale and Design: Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Zodasiran Efficacy and Safety in Adolescents and Adults with Homozygous Familial Hypercholesterolemia (2025 · Circulation · 被引 1)
• Zodasiran (ARO-ANG3), an investigational RNAi therapeutic, demonstrates profound and durable reductions in LDL-cholesterol, apolipoprotein B, and ANGPTL3 in patients with HoFH; gateway final results (2025 · Atherosclerosis · 被引 1)
• Development of a dual functional RNAi therapeutic, ARO-DIMER-PA, for mixed hyperlipidemia (2025 · Journal of clinical lipidology · 被引 1)